. Laboratory values, by date, for 2 HIV-positive men who used nonprescription anabolic-androgenic steroids. 3 and an HIV-1 RNA load of !75 copies/mL who had been taking a regimen of lopinavir-ritonavir (400 mg of lopinavir and 100 mg of ritonavir twice daily); abacavir, lamivudine, and zidovudine (300 mg of abacavir, 150 mg of lamivudine, and 300 mg of zidovudine twice daily); and tenofovir (300 mg daily) since October 2002. Other past medical history included allergic rhinitis and insomnia, for which he received fexofenadine, intranasal fluticasone, and zolpidem.
He started using illicit He started a 6-week regimen of AAS precursors in July 2004. In addition to his prescribed testosterone, he started taking an over-the-counter muscle-building product (Winni Depot, German American Technologies; 2 pills 3 times per day; each pill contained 10 mg of methyl-1-testosterone, 50 mg of 5-androstenediol, 50 mg of beta-hydroxyecdysone, and 100 mg of a "proprietary amplifier blend" [6] ) and a 5% liposomal steroid solution (Finigenex, PharmaGenX; 6 mL 3 times per day; the solution contained 25 mg/mL of 19-norandrosta-4, 9-diene-3, and 17-dione). He discontinued use of these compounds in September 2004. The results of his laboratory tests are shown in table 1. He did not abuse alcohol or start taking any other new medications, and his viral hepatitis serologic test results and glucose levels were unremarkable. When he was taking these steroid supplements, his 10-year calculated risk of coronary heart disease rose from 1% to 10% [5] .
According to a recent review of the literature about AAS use, the prevalence of steroid use among active individuals ranges between 6.2% and 38.4%, and the prevalence among inactive individuals ranges between 0.4% and 9.6%. The prevalence rates obtained from many of the studies did not distinguish single use from prolonged use [7] . Only 1 study has specifically looked at AAS use by HIV-positive, homosexual men; it was found that the prevalence of AAS use was 31.7% [8] . The study did not differentiate therapeutic from nonprescription use.
Lipid and transaminase level elevations have been reported in AAS users [9] . We convinced our patients to discontinue AAS use by explaining the long-term cardiovascular implications of their lipid level abnormalities in particular. The importance of asking patients about steroid use is highlighted by a recent study that shows that only 44% of AAS users had revealed their use to physicians [10] .
Patient 1 obtained his steroids illegally from an individual supplier; patient 2 bought his (now banned) steroid precursors over the counter. Internet sources are also readily available. Using the Internet search engine Google, we found that the phrase "buy steroids" resulted in 1,900,000 hits. Many of these Web sites provide AAS dosing instructions and regimens, but downplay the drugs' potential hazards.
In summary, prevalence data on AAS use in HIV-positive, homosexual men is sparse, but limited results show that the prevalence of use may be high. AAS use may confound interpretation of liver and lipid level abnormalities in HIV-infected patients who receive HAART. AASs are readily available, and vendors rarely reveal their dangers. HIV care providers should routinely screen their patients for steroid use and educate them regarding the drugs' adverse effects.
The Role of Klebsiella pneumoniae in Lung Abscesses: A Geographic Phenomenon (for Now!)
Sir-We wish to comment on the informative article by Wang et al. [1] from Taiwan and the erudite editorial by Bartlett [2] concerning the role of Klebsiella pneumoniae and anaerobes in lung abscesses. The conclusions of both the article and editorial comment on the changing bacteriologic characteristics of lung abscess, with a possible decreased role of anaerobes.
We want to emphasize one notable finding that Wang et al. [1] mentioned in the discussion section of their article: the high incidence of isolation of K. pneumoniae from patients with necrotizing pneumonia and lung abscess is associated with geographic location. In an observational study of 455 cases of bacteremia from all 6 inhabitable continents, K. pneumoniae infection was found to be more invasive in patients in Taiwan, as judged by severity of illness and mortality. South Africa also had more cases of invasive pneumonia.
In Taiwan, a distinctive clinical syndrome of liver abscess with bacteremia and metastatic lesions has been well described [3] [4] [5] [6] . It appears that K. pneumoniae in Taiwan and South Africa is notably more virulent than K. pneumoniae strains in North America, Europe, South America, or the Middle East. In mouse lethality experiments, we found that K. pneumoniae isolates recovered from blood cultures for patients residing in Taiwan and South Africa were more likely to cause death in mice than were K. pneumoniae isolates recovered from bacteremic patients in other parts of the world, including South America, North America, Europe, Australia, and
